Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 199 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Tarlatamab MOST POPULAR Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with... April 9, 2026 Apalutamide Plus ADT Demonstrates a Rapid, Deep, and Durable PSA Decline... March 29, 2023 Veteran Drops To The Ground When He Hears How Much His... January 31, 2020 Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis,... February 10, 2026 Load more HOT NEWS New obesity strategy is a ‘landmark day for the nation’s health’... Results of Continuous vs Intermittent Dosing Schedules of BRAF/MEK Inhibitor Combination... ESMO World Congress on Gastrointestinal Cancer 2021, 30 June – 3... Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α
